Evidence map›Paper›PMID 30332784›Full record

ArticleViruses2018

Current Perspectives on High-Throughput Sequencing (HTS) for Adventitious Virus Detection: Upstream Sample Processing and Library Preparation.

Siemon H Ng, Cassandra Braxton, Marc Eloit, Szi Fei Feng, Romain Fragnoud, Laurent Mallet, Edward T Mee, Sarmitha Sathiamoorthy, Olivier Vandeputte, Arifa S Khan

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Viral Clearance: Safety and Efficiency of Biopharmaceuticals.Therapeutic innovation & regulatory science · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Report of the third conference on next-generation sequencing for adventitious virus detection in biologics for humans and animals.Biologicals : journal of the International Association of Biological Standardization · 2023
    Article
  9. Article
  10. mSphere · 2021
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Siemon H NgProduct Research and Development, Analytical Sciences, Sanofi Pasteur, Toronto, ON L4J 7Z4, Canada. siemon.ng@sanofi.com.
Cassandra BraxtonBiogen, Inc., Research Triangle Park, NC 27709, USA. cassandra.braxton@biogen.com.
Marc EloitPathoQuest, 75015 Paris, France. marc.eloit@pathoquest.com.
Szi Fei FengMerck & Co., Inc., West Point, PA 19486, USA. szifei_feng@merck.com.
Romain FragnoudTexcell, Genavenir 5 1, Rue Pierre Fontaine, 91058 évry, France. rfragnoud@texcell.fr.
Laurent MalletProduct Research and Development, Analytical Sciences, Sanofi Pasteur, 69280 Marcy L'Etoile, France. laurent.mallet@sanofi.com.
Edward T MeeDivision of Virology, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency, South Mimms, Hertfordshire EN6 3QG, UK. edward.mee@nibsc.org.
Sarmitha SathiamoorthyProduct Research and Development, Analytical Sciences, Sanofi Pasteur, Toronto, ON L4J 7Z4, Canada. sarmitha.sathiamoorthy@gmail.com.
Olivier VandeputteAnalytical Research and Development, GSK, 1330 Rixensart, Belgium. olivier.x.vandeputte@gsk.com.
Arifa S KhanDivision of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. arifa.khan@fda.hhs.gov.
Sanofi (Canada) · CAInserm · FRNational Institute for Biological Standards and Control · GBSanofi (France) · FRTriangle · USUnited States Food and Drug Administration · USUnited States Military Academy · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A key step for broad viral detection using high-throughput sequencing (HTS) is optimizing the sample preparation strategy for extracting viral-specific nucleic acids since viral genomes are diverse: They can be single-stranded or double-stranded RNA or DNA, and can vary from a few thousand bases to over millions of bases, which might introduce biases during nucleic acid extraction. In addition, viral particles can be enveloped or non-enveloped with variable resistance to pre-treatment, which may influence their susceptibility to extraction procedures. Since the identity of the potential adventitious agents is unknown prior to their detection, efficient sample preparation should be unbiased toward all different viral types in order to maximize the probability of detecting any potential adventitious viruses using HTS. Furthermore, the quality assessment of each step for sample processing is also a critical but challenging aspect. This paper presents our current perspectives for optimizing upstream sample processing and library preparation as part of the discussion in the Advanced Virus Detection Technologies Interest group (AVDTIG) The topics include: use of nuclease treatment to enrich for encapsidated nucleic acids, techniques for amplifying low amounts of virus nucleic acids, selection of different extraction methods, relevant controls, the use of spike recovery experiments, and quality control measures during library preparation.

Indexed as

Gene LibraryAnimalsDNA, ViralGenome, ViralHigh-Throughput Nucleotide SequencingHumansRNA, ViralSpecimen HandlingVirionVirus DiseasesVirusesDNA, ViralRNA, Viraladventitious virusbiologicshigh-throughput sequencingnext-generation sequencingsample preparationvirus detection

Identifiers

PMID30332784
PMCPMC6213814
OpenAlexW2896173991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.